|
Butyrylcholinesterase deficiency
|
0.720 |
Biomarker
|
disease |
BEFREE |
Sensitivity of butyrylcholinesterase knockout mice to (--)-huperzine A and donepezil suggests humans with butyrylcholinesterase deficiency may not tolerate these Alzheimer's disease drugs and indicates butyrylcholinesterase function in neurotransmission.
|
17194517 |
2007 |
|
Butyrylcholinesterase deficiency
|
0.720 |
Biomarker
|
disease |
BEFREE |
The butyrylcholinesterase knockout mouse as a model for human butyrylcholinesterase deficiency.
|
18056867 |
2008 |
|
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
The majority of derivatives inhibit AChE more efficiently than BuChE and are comparable or superior to rivastigmine-an established cholinesterases inhibitor used in the treatment of Alzheimer's disease.
|
31694272 |
2019 |
|
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Progression to AD and hippocampal volumetric loss was greatest in participants who carried both APOE epsilon4 and BCHE-K alleles and lowest in BCHE-K carriers without the APOE epsilon4 allele.
|
18334913 |
2008 |
|
Alzheimer's Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Clinical meaningfulness of Alzheimer's Disease Assessment Scale-Cognitive subscale change in relation to goal attainment in patients on cholinesterase inhibitors.
|
28341540 |
2017 |
|
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Since deficit of acetylcholine has been evidenced in patients of Alzheimer's disease (AD), cholinesterase inhibitors are currently the most prescribed drugs for the treatment of AD.
|
28714400 |
2018 |
|
Alzheimer's Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In the present study, we investigated the influence of glycosylation of components of <i>C. obtusifolia</i> and structure-activity relationships (SARs) with respect to the inhibition of acetylcholinesterase (AChE), butyrylcholinesterase (BChE), and β-site amyloid precursor protein (APP)-cleaving enzyme 1 (BACE1), which are related to Alzheimer's disease (AD).All six <i>C. obtusifolia</i>-derived compounds, rubrofusarin (<b>1</b>), rubrofusarin 6-<i>O-</i>β-d-glucopyranoside (<b>2</b>), rubrofusarin 6-<i>O-</i>β-d-gentiobioside (<b>3</b>), nor-rubrofusarin 6-<i>O-</i>β-d-glucoside (<b>4</b>), isorubrofusarin 10-<i>O-</i>β-d-gentiobioside (<b>5</b>), and rubrofusarin 6-<i>O-</i>β-d-triglucoside (<b>6</b>) showed promising inhibitory activity against AChE/BACE1.
|
29283428 |
2017 |
|
Alzheimer's Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Differential CSF butyrylcholinesterase levels in Alzheimer's disease patients with the ApoE epsilon4 allele, in relation to cognitive function and cerebral glucose metabolism.
|
16973370 |
2006 |
|
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
The inhibition of cholinesterase enzymes is one of the promising strategies to manage several neurological disorders that include Alzheimer's disease (AD).
|
31258059 |
2019 |
|
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Butyrylcholinesterase (BChE) plays an important role in the progression of the Alzheimer's disease.
|
31347933 |
2019 |
|
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
The enzyme butyrylcholinesterase (BChE) and the human cannabinoid receptor 2 (hCB<sub>2</sub>R) represent promising targets for pharmacotherapy in the later stages of Alzheimer's disease.
|
29400965 |
2018 |
|
Alzheimer's Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In this study we report the results of family-based analyses for polymorphisms of five such candidates on chromosomes 2 (interleukin-1beta, IL-1B), 3 (butyrylcholinesterase, BCHE), 11 (cathepsin D, CTSD; Fe65, APBB1) and 12 (lipoprotein receptor-related protein-1, LRP1) that were all suggested to be associated with AD in recent case-control studies.
|
11113613 |
2000 |
|
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Comparative safety and effectiveness of cholinesterase inhibitors and memantine for Alzheimer's disease: a network meta-analysis of 41 randomized controlled trials.
|
30591071 |
2018 |
|
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Novelty of our findings are the inhibitory action of the ethanol extract of A. cotula aerial parts on key enzymes associated with Alzheimer's disease (acetyl cholinesterase, butyryl cholinesterase), type 2 diabetes (α-amylase, α-glucosidase), and skin hyperpigmentation disorders (tyrosinase).
|
31121457 |
2019 |
|
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Investigating 1,2,3,4,5,6-hexahydroazepino[4,3-b]indole as scaffold of butyrylcholinesterase-selective inhibitors with additional neuroprotective activities for Alzheimer's disease.
|
31158754 |
2019 |
|
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
As part of our ongoing efforts in discovering potential bioactive compounds from G. repens, we have studied the isolation, identification, and quantification of a new class of cholinesterase inhibitor from G. repens for Alzheimer's disease (AD).
|
31028989 |
2019 |
|
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Extra-virgin olive oils (EVOOs) obtained from 'Brava' and 'Mansa', varieties recently identified from Galicia (northwestern Spain), were selected for in vitro screening to evaluate their capacity to inhibit key enzymes involved in Alzheimer's disease (AD) (acetylcholinesterase (AChE), butyrylcholinesterase (BuChE) and 5-lipoxygenase (5-LOX)), major depressive disorder (MDD) and Parkinson's disease (PD) (monoamine oxidases: <i>h</i>MAO-A and <i>h</i>MAO-B respectively).
|
29561824 |
2018 |
|
Alzheimer's Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The antioxidant 2,3-dichloro,5,8-dihydroxy,1,4-naphthoquinone inhibits acetyl-cholinesterase activity and amyloid β<sub>42</sub> aggregation: A dual target therapeutic candidate compound for the treatment of Alzheimer's disease.
|
31820491 |
2019 |
|
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Dual functional cholinesterase and PDE4D inhibitors for the treatment of Alzheimer's disease: Design, synthesis and evaluation of tacrine-pyrazolo[3,4-b]pyridine hybrids.
|
31281020 |
2019 |
|
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Cholinesterase inhibitors and a partial NMDA receptor antagonist (memantine) have been identified as potential treatment options for AD.
|
21166677 |
2011 |
|
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Cholinesterase inhibitors appear to offer benefit for people with Down syndrome and Alzheimer's disease that is comparable with sporadic Alzheimer's disease; a trial to test the effect of earlier treatment (prodromal Alzheimer's disease) in Down syndrome may be indicated.
|
29486820 |
2018 |
|
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
In this study, pteryxin, which was previously isolated from the fruits of Mutellina purpurea, was investigated for its inhibitory potential against acetylcholinesterase (AChE) and butyrylcholinesterase (BChE), which are the key enzymes in the pathology of Alzheimer's disease (AD).
|
28286309 |
2017 |
|
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
These results suggest that TD compounds might be considered as attractive multi-target cholinesterase inhibitor and will play important roles in the treatment of AD.
|
30954836 |
2019 |
|
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Approximately, 15% of the AD population may exhibit an abnormal metabolism of cholinesterase inhibitors; about 50% of this population cluster would show an ultrarapid metabolism, requiring higher doses of cholinesterase inhibitors to reach a therapeutic threshold, whereas the other 50% of the cluster would exhibit a poor metabolism, displaying potential adverse events at low doses.
|
17908053 |
2007 |
|
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
BCHE has been found in senile plaques and this new association of genetic variation at the BCHE locus with Aβ burden in humans may have implications for potential disease-modifying effects of BCHE-modulating agents in the AD spectrum.
|
23419831 |
2014 |